Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of itacitinib plus corticosteroids for first-line acute graft-versus-host disease
MOH_2017-10-24_001870Phase 3Not yet recruiting
- Sponsor
- Incyte
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Corticosteroids + itacitinib with Corticosteroids + placebo (2 arms). Primary endpoint: Overall response rate at Day 28. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2017-10-24_001870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-24_001870.